Clinical trials: Healthy Glucose
Obesity, Impaired Glucose Tolerance
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes.
- Trial name
- NCT00456885
- Testing
- exenatide
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons…
- Trial name
- NCT01077323
- Testing
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Where
- United States
- Volunteers
- 363,766 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes Mellitus
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of…
- Trial name
- NCT02411929
- Testing
- Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Child Mental Disorders, Obesity
Healthy Bodies, Healthy Kids
The US prevalence of childhood-onset obesity and type 2 diabetes, both predictors of cardiovascular risk, have increased to epidemic proportions in recent decades.
- Conditions
- Child Mental Disorders, Obesity, Metabolic Syndrome
- Trial name
- NCT01222494
- Testing
- Behavioral Weight Loss, Diet and Exercise Education
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes, Wound Infection
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
This study will determine the tissue penetration of ceftolozane/tazobactam (Zerbaxa, Merck \& Co.), a novel β-lactam/β-lactamase combination antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic…
- Conditions
- Diabetes, Wound Infection, Healthy Volunteers
- Trial name
- NCT02620774
- Testing
- Ceftolozane/tazobactam, Microdialysis Catheter Insertion
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, Healthy
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later…
- Trial name
- NCT01607450
- Testing
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Type 2 Diabetes, Diabetes
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers.
- Trial name
- NCT00339833
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Diabetes Mellitus, Type 2, Medication Adherence
Reinforcement Learning in Diabetes Mellitus Trial
Reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize individuals' behaviors using…
- Trial name
- REINFORCE (NCT04473326)
- Testing
- Reinforcement Learning
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin.
- Trial name
- NCT03296800
- Testing
- Bexagliflozin, Probenecid, Rifampin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Theracos
Diabetes Mellitus, Type 2
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants
The purpose of this study is to look at how the body processes oral contraceptive (OC), using Ortho-Cyclen, as a commonly prescribed combination oral contraceptive in healthy female participants, and the effect of dulaglutide on…
- Trial name
- NCT01458210
- Testing
- Ortho-Cyclen, Dulaglutide
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in healthy subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01473953
- Testing
- liraglutide-depot
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01476345
- Testing
- LY2963016, Lantus
- Where
- South Africa
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bioequivalence, Fixed Dose Combination Tablets
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
- Conditions
- Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
- Trial name
- NCT02637037
- Testing
- dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8521. Part 1 primary hypothesis: Administration of single subcutaneous (SC) doses of MK-8521 is sufficiently safe and well- tolerated…
- Trial name
- NCT02055547
- Testing
- MK-8521 35μg, MK-8521 100μg, MK-8521 125μg
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
PreDiabetes, Hyperglycemia
Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs
The purpose of this research study is to compare the effectiveness of a fully automated digital diabetes prevention program to standard of care human coach-based diabetes prevention programs for promoting clinically meaningful…
- Conditions
- PreDiabetes, Hyperglycemia, Glucose, High Blood, Overweight
- Trial name
- NCT05056376
- Testing
- Digital Diabetes Prevention Program (dDPP), Human Coach-based Diabetes Prevention Program (hDPP)
- Where
- 2 sites in United States
- Volunteers
- 368 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 2
A First-in-Human Study of LY3009385 in Healthy Participants
The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented.
- Trial name
- NCT01477567
- Testing
- LY3009385
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Wound Infection
Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
This study will determine the tissue penetration of tedizolid (Sivextro, Merck \& Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound…
- Conditions
- Diabetes, Wound Infection, Healthy Volunteers
- Trial name
- NCT02620787
- Testing
- Tedizolid, Microdialysis Catheter Insertion
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital